Prenetics Global Limited (NASDAQ:PRE – Free Report) – Analysts at Zacks Research decreased their Q3 2026 earnings estimates for Prenetics Global in a research note issued to investors on Tuesday, August 18th. Zacks Research analyst B. Sorensen now forecasts that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Prenetics Global’s Q4 2026 earnings at $0.20 EPS, FY2026 earnings at ($1.14) EPS and Q1 2027 earnings at ($0.13) EPS.
Prenetics Global (NASDAQ:PRE – Get Free Report) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The business had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.85 million.
Get Our Latest Stock Report on PRE
Prenetics Global Price Performance
NASDAQ PRE opened at $17.97 on Friday. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The firm has a market cap of $303.15 million, a P/E ratio of -4.32 and a beta of 0.26. The stock’s 50-day moving average is $19.08 and its 200-day moving average is $18.88.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN bought a new stake in shares of Prenetics Global in the 4th quarter valued at about $47,000. State of Wyoming acquired a new stake in shares of Prenetics Global in the first quarter valued at approximately $48,000. JPMorgan Chase & Co. acquired a new position in shares of Prenetics Global during the 3rd quarter worth approximately $65,000. Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the 4th quarter valued at $170,000. Finally, T3 Companies LLC acquired a new stake in Prenetics Global during the 4th quarter valued at $170,000. Institutional investors own 25.01% of the company’s stock.
Key Headlines Impacting Prenetics Global
Here are the key news stories impacting Prenetics Global this week:
- Positive Sentiment: IM8 reported Q2 2026 revenue growth of 288% year over year and raised its FY 2026 revenue guidance to $220–$230 million. Prenetics also initiated FY 2027 revenue guidance of at least $400 million, signaling management expects rapid growth to continue. IM8 Q2 2026 revenue and guidance article
- Positive Sentiment: Actress and producer Lily Collins will become IM8’s first film-and-television global ambassador and a Prenetics shareholder under a multi-year partnership. Her reach of more than 33 million social-media followers is expected to broaden IM8’s exposure, particularly among female consumers, beyond its existing sports-focused ambassador roster. Lily Collins IM8 partnership article
- Positive Sentiment: Management said IM8 has delivered more than 57 million servings, ships approximately 200,000 servings daily across 46 countries, and generated 54% of revenue outside the United States. Prenetics also reported positive consolidated adjusted free cash flow in July and expects to remain positive through the third quarter and beyond.
- Neutral Sentiment: Analyst estimate changes were mixed: Sidoti modestly raised its Q1 2028 EPS forecast to $0.29 but trimmed its FY 2028 estimate to $2.12, while Zacks lowered its FY 2027 EPS estimate to $1.49 from $1.56. The revisions do not materially change the broader growth narrative.
- Negative Sentiment: The elevated 2026–2027 targets are forward-looking and depend on sustained IM8 demand, successful product launches—including hydration and gummies—and effective marketing. Prenetics remains unprofitable, with consensus estimates calling for a current-year loss of $1.28 per share, leaving execution risk significant.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
See Also
- Five stocks we like better than Prenetics Global
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
